BeiGene
BGNE
#968
Rank
NZ$35.44 B
Marketcap
$320.89
Share price
2.21%
Change (1 day)
14.67%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeiGene (BGNE)

Revenue in 2024 (TTM): NZ$5.55 Billion

According to BeiGene 's latest financial reports the company's current revenue (TTM ) is NZ$5.86 Billion. In 2023 the company made a revenue of NZ$3.88 Billion an increase over the revenue in the year 2022 that were of NZ$2.23 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeiGene from 2015 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$5.55 B42.95%
2023 NZ$3.88 B74.34%
2022 NZ$2.23 B29.84%
2021 NZ$1.71 B299.93%
2020 NZ$0.42 B-32.35%
2019 NZ$0.63 B114.91%
2018 NZ$0.29 B-12%
2017 NZ$0.33 B21629.76%
2016 NZ$1.54 M-88.02%
2015 NZ$12.89 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
NZ$0.39 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.25 B-78.55%๐Ÿ‡บ๐Ÿ‡ธ USA